Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Inclusion Criteria: * Signed informed consent document on file; * Age over 60 years; * Age \< 60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol level in the postmenopausal range; * Patients with metastatic or locally advanced disease not amenable to therapy with Curative intent * ER + and/or PgR +; * Duration of adjuvant non-aromatase inhibitors treatment should be at least 2 years or more; * WHO performance status 0, 1 or 2; * Patients with life expectancy of more than 3 months. Exclusion Criteria: * Presence of life-threatening metastatic visceral disease; * Previous systemic chemotherapy for advanced breast cancer; * Received systemic endocrine therapy for advanced disease; * Extensive radiation therapy within the last 4 weeks ; * Platelets \< 100\*109 / L,Total bilirubin no less than 1.5ULRR, ALT or AST no less than 2.5ULRR if no demonstrable liver metastases or no less than 5ULRR in presence of liver metastases; * Severe renal impairment, bleeding diathesis, long-term anticoagulant therapy; * History of hypersensitivity to active or inactive excipients of fulvestrant, Exemestane and/or castor oil.